UCB Plans $5B U.S. Biologics Plant Investment
Slice of Manufacturing Team
Jun 17, 2025
Key highlights
- UCB to invest ~$5 billion in a new U.S. biologics manufacturing facility
- 300 permanent jobs and 500+ construction roles to be created
- Feasibility study underway for optimal U.S. site with strong talent and innovation ecosystems
- Supports UCB's expanding U.S. patient base and innovation pipeline
- Part of $4.5B U.S. investment since 2017, alongside 15 FDA approvals
Source: PR Newswire
Notable Quote
“ At UCB, we are guided by a clear purpose—to create value for patients now and into the future. This investment reflects our growing impact in the US and our ambition to bring our forthcoming pipeline to patients around the world. By expanding our biologics manufacturing footprint, we're not only reinforcing our global supply chain—we're also contributing to the vitality of biomedical innovation, high-skilled jobs, and long-term economic impact in the US. ”
Jean-Christophe Tellier, CEO at UCB
Why This Matters
UCB's $5 billion commitment to build a new biologics facility in the United States marks a major milestone in the company’s global growth strategy. As one of the world’s leading biopharmaceutical players in severe diseases, this expansion enhances manufacturing resilience, supports future drug delivery, and strengthens local ecosystems with high-value employment and investment. It also underscores the strategic importance of the U.S. market for UCB’s innovation trajectory and economic contributions.
